SBIR/STTR Research Award
Not Available
Award amount
$297,532Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BioSavita, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PHS2010-1
- Topic code
- NCI
Research abstract
ApoLife is developing yeast platform-Twin Cassette yeast vectors for cost effective manufacturing of antibodies. Using recent collaboration with a company with proprietary S. cerevisiae yeast strains producing homogeneous human N-linked glycosylated proteins, ApoLife will develop commercial scale process for cost effective manufacturing of Campth, anticancer antibody, as a biogeneric antibody candidate. ApoLife has expressed Campath genes in yeast system.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis